Deep Shukla in Medical News:
After a lull of nearly 2 decades, the Food and Drug Administration (FDA) has approved some novel drugs for the treatment of Alzheimer’s disease since 2021. Most of these drugs are antibody therapies targeting toxic protein aggregates in the brain. Their approval has sparked enthusiasm and controversy in equal measure. The core question remains: Are these drugs making a real difference? In this Special Feature, we investigate. Alzheimer’s disease is a neurodegenerative disease that involves a gradual and irreversible decline in memory, thinking, and, eventually, the ability to perform daily activities. Aging is the leading risk factor for Alzheimer’s disease, and a rapidly aging population has made it a public health crisis.
In 2019, 57 millionTrusted Source individuals around the globe had Alzheimer’s disease, and this number is expected to reach 153 million by 2050. This underscores the need for disease-modifying treatments that produce a lasting change in the trajectory of this disease, slowing its progression. However, until recently, efforts to develop disease-modifying therapies for Alzheimer’s disease have not been successful. Most of the clinical research to develop disease-modifying therapies for Alzheimer’s has focused on targeting the beta-amyloid protein, whose abnormal accumulation is generally considered to lead to the development of this neurodegenerative disorder.
More here.
Enjoying the content on 3QD? Help keep us going by donating now.